BNP Paribas Financial Markets Purchases 215,189 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID)

BNP Paribas Financial Markets grew its holdings in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 4,128.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 220,401 shares of the company’s stock after buying an additional 215,189 shares during the period. BNP Paribas Financial Markets’ holdings in Ovid Therapeutics were worth $260,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Driehaus Capital Management LLC bought a new stake in Ovid Therapeutics during the second quarter worth about $1,077,000. GSA Capital Partners LLP lifted its holdings in shares of Ovid Therapeutics by 118.0% during the third quarter. GSA Capital Partners LLP now owns 260,509 shares of the company’s stock valued at $307,000 after purchasing an additional 141,002 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Ovid Therapeutics in the 3rd quarter worth approximately $102,000. DCF Advisers LLC grew its stake in shares of Ovid Therapeutics by 111.6% in the 2nd quarter. DCF Advisers LLC now owns 41,750 shares of the company’s stock worth $32,000 after buying an additional 22,020 shares during the last quarter. Finally, FFT Wealth Management LLC increased its position in Ovid Therapeutics by 18.2% during the 2nd quarter. FFT Wealth Management LLC now owns 489,552 shares of the company’s stock valued at $377,000 after buying an additional 75,530 shares in the last quarter. 72.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on OVID shares. William Blair upgraded shares of Ovid Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Ovid Therapeutics in a research note on Wednesday, December 4th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Ovid Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $4.04.

Ovid Therapeutics Trading Up 1.9 %

Shares of NASDAQ:OVID opened at $1.05 on Tuesday. The stock’s 50-day simple moving average is $1.14 and its two-hundred day simple moving average is $1.22. The stock has a market capitalization of $74.56 million, a price-to-earnings ratio of -2.23 and a beta of 0.29. Ovid Therapeutics Inc. has a 52-week low of $0.68 and a 52-week high of $4.10. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.66 and a current ratio of 5.66.

Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Tuesday, November 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.15 million. Analysts expect that Ovid Therapeutics Inc. will post -0.48 EPS for the current year.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.